Center for Substance Abuse Prevention; Notice of Meeting, 28623 [2010-12208]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 98 / Friday, May 21, 2010 / Notices
emcdonald on DSK2BSOYB1PROD with NOTICES
public about that topic. FDA uses the
feedback provided by the public to
update this resource.
Phase II is the subject of this
document and is described in more
detail in section II of this document.
Phase III of the Transparency
Initiative will address ways FDA can
become more transparent to regulated
industry, to foster a more efficient and
cost-effective regulatory process. The
Task Force solicited comments from the
public on this topic in March 2010 (75
FR 11893, March 12, 2010) and draft
proposals from this phase are expected
in the summer of 2010.
II. Phase II: Public Disclosure
The second phase of the Transparency
Initiative relates to FDA’s policies on
disclosure of information to the public
about FDA activities. FDA is releasing a
report that contains 21 draft proposals
that we are issuing for public comment.
The draft proposals, along with
background material, can be found on
the FDA Web site at www.fda.gov/
transparency. FDA is accepting
comments from the public on the draft
proposals on the FDA Web site as well
as through the docket (see section III of
this notice).
The Task Force solicited comments
from the public about information FDA
should provide to the public about what
FDA is doing, the bases for the agency’s
decisions, and the processes used to
make agency decisions. The Task Force
reviewed and considered all the
comments received from a range of
stakeholders. The Task Force also
identified on its own initiative ways to
improve transparency that are reflected
in the report.
In the report, the Task Force makes
available for public comment 21 draft
proposals for changes in policy related
to the disclosure of information FDA
has in its possession, while supporting
the redaction of trade secrets and
individually identifiable patient
information from all documents
proposed for disclosure. Other topics on
which FDA plans to make changes or on
which the Task Force is not proposing
policy changes at this time are
discussed in the ‘‘Other Areas of Public
Comment’’ section of the report.
After considering public comment on
the draft proposals, the Task Force will
recommend specific proposals to the
Commissioner for consideration, and
then FDA will announce which of the
proposals it will implement, and the
projected timeframe for implementation.
Some of the draft proposals may require
extensive resources to implement, and
some may require changes to regulations
or legislation. Therefore, in addition to
VerDate Mar<15>2010
16:40 May 20, 2010
Jkt 220001
28623
input on the content of the proposals
and whether the Task Force has struck
the right balance with respect to the
draft proposals, FDA is seeking input on
how the agency should prioritize the
proposals, if it decided to implement
them. The Task Force will consider
feasibility and priority, considering
other agency priorities that require
resources, when developing its specific
recommendations for the Commissioner.
Substantive program information, a
summary of the meeting, and a roster of
Committee members may be obtained
either by accessing the SAMHSA
Committee’s Web site at https://
www.samhsa.gov/council/csap/
csapnac.aspx as soon as possible after
the meeting, or by contacting CSAP
National Advisory Council’s Designated
Federal Official, Ms. Tia Haynes (see
contact information below).
III. Request for Comments
Committee Name: Substance Abuse and
Mental Health Services Administration,
Center for Substance Abuse Prevention
National Advisory Council.
Date/Time/Type: June 9, 2010, 1 p.m. to 4
p.m.: Closed.
Place: 1 Choke Cherry Road, Conference
Room 4–1058, Rockville, Maryland 20857.
Contact: Tia Haynes, Designated Federal
Official, SAMHSA/CSAP National Advisory
Council, 1 Choke Cherry Road, Room 4–1066,
Rockville, MD 20857, Telephone: (240) 276–
2436; FAX: (240) 276–2430. E-mail:
tia.haynes@samhsa.hhs.gov.
FDA is interested in receiving
comments from the public about the
content of the draft proposals as well as
on which draft proposals should be
given priority. Interested persons may
submit to the Division of Dockets
Management (see ADDRESSES) either
electronic or written comments
regarding this document. It is only
necessary to send one set of comments.
It is no longer necessary to send two
copies of mailed comments. Identify the
draft proposal which your comment
addresses by the number assigned to
that proposal. Identify comments with
the docket number found in brackets in
the heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
Comments can also be submitted on
each draft proposal via the FDA Web
site, www.fda.gov/transparency.
Dated: May 17, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–12314 Filed 5–19–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Center for Substance Abuse
Prevention; Notice of Meeting
Pursuant to Public Law 92–463,
notice is hereby given that the
Substance Abuse and Mental Health
Services Administration’s (SAMHSA)
Center for Substance Abuse Prevention
(CSAP) National Advisory Council will
meet on June 9, 2010 from 1 p.m. to 4
p.m. via teleconference.
The meeting will include discussion
and evaluation of grant applications
reviewed by Initial Review Groups.
Therefore, the meeting will be closed to
the public as determined by the
Administrator, SAMHSA, in accordance
with Title 5 U.S.C. 552b(c)(6) and 5
U.S.C. App. 2, Section 10(d).
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
Toian Vaughn,
Committee Management Officer, Substance
Abuse and Mental Health Services
Administration.
[FR Doc. 2010–12208 Filed 5–20–10; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflict: Brain Function and Structure.
Date: June 8, 2010.
Time: 9 a.m. to 9 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Kevin Walton, PhD,
Scientific Review Officer, Center for
E:\FR\FM\21MYN1.SGM
21MYN1
]]>Agencies
[Federal Register Volume 75, Number 98 (Friday, May 21, 2010)]
[Notices]
[Page 28623]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-12208]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Center for Substance Abuse Prevention; Notice of Meeting
Pursuant to Public Law 92-463, notice is hereby given that the
Substance Abuse and Mental Health Services Administration's (SAMHSA)
Center for Substance Abuse Prevention (CSAP) National Advisory Council
will meet on June 9, 2010 from 1 p.m. to 4 p.m. via teleconference.
The meeting will include discussion and evaluation of grant
applications reviewed by Initial Review Groups. Therefore, the meeting
will be closed to the public as determined by the Administrator,
SAMHSA, in accordance with Title 5 U.S.C. 552b(c)(6) and 5 U.S.C. App.
2, Section 10(d).
Substantive program information, a summary of the meeting, and a
roster of Committee members may be obtained either by accessing the
SAMHSA Committee's Web site at https://www.samhsa.gov/council/csap/csapnac.aspx as soon as possible after the meeting, or by contacting
CSAP National Advisory Council's Designated Federal Official, Ms. Tia
Haynes (see contact information below).
Committee Name: Substance Abuse and Mental Health Services
Administration, Center for Substance Abuse Prevention National
Advisory Council.
Date/Time/Type: June 9, 2010, 1 p.m. to 4 p.m.: Closed.
Place: 1 Choke Cherry Road, Conference Room 4-1058, Rockville,
Maryland 20857.
Contact: Tia Haynes, Designated Federal Official, SAMHSA/CSAP
National Advisory Council, 1 Choke Cherry Road, Room 4-1066,
Rockville, MD 20857, Telephone: (240) 276-2436; FAX: (240) 276-2430.
E-mail: tia.haynes@samhsa.hhs.gov.
Toian Vaughn,
Committee Management Officer, Substance Abuse and Mental Health
Services Administration.
[FR Doc. 2010-12208 Filed 5-20-10; 8:45 am]
BILLING CODE 4162-20-P
